Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer: the Penelope-B trial
PURPOSE - - About one third of patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer who have residual invasive disease after neoadjuvant chemotherapy (NACT) will relapse. Thus, additional therapy is needed. Palbociclib is a cyclin-dependent kinase...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
April 1, 2021
|
| In: |
Journal of clinical oncology
Year: 2021, Jahrgang: 39, Heft: 14, Pages: 1518-1530 |
| ISSN: | 1527-7755 |
| DOI: | 10.1200/JCO.20.03639 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1200/JCO.20.03639 Verlag, lizenzpflichtig, Volltext: https://ascopubs.org/doi/10.1200/JCO.20.03639 
|
| Verfasserangaben: | Sibylle Loibl; Frederik Marmé; Miguel Martin; Michael Untch; Hervé Bonnefoi; Sung-Bae Kim; Harry Bear; Nicole McCarthy; Mireia Melé Olivé; Karen Gelmon; José García-Sáenz; Catherine M. Kelly; Toralf Reimer; Masakazu Toi; Hope S. Rugo; Carsten Denkert; Michael Gnant; Andreas Makris; Maria Koehler; Cynthia Huang-Bartelett; Maria Jose Lechuga Frean; Marco Colleoni; Gustavo Werutsky; Sabine Seiler; Nicole Burchardi; Valentina Nekljudova; and Gunter von Minckwitz |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1772026336 | ||
| 003 | DE-627 | ||
| 005 | 20230427160057.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210929s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.20.03639 |2 doi | |
| 035 | |a (DE-627)1772026336 | ||
| 035 | |a (DE-599)KXP1772026336 | ||
| 035 | |a (OCoLC)1341421582 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Loibl, Sibylle |e VerfasserIn |0 (DE-588)12433024X |0 (DE-627)085790508 |0 (DE-576)294122753 |4 aut | |
| 245 | 1 | 0 | |a Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer |b the Penelope-B trial |c Sibylle Loibl; Frederik Marmé; Miguel Martin; Michael Untch; Hervé Bonnefoi; Sung-Bae Kim; Harry Bear; Nicole McCarthy; Mireia Melé Olivé; Karen Gelmon; José García-Sáenz; Catherine M. Kelly; Toralf Reimer; Masakazu Toi; Hope S. Rugo; Carsten Denkert; Michael Gnant; Andreas Makris; Maria Koehler; Cynthia Huang-Bartelett; Maria Jose Lechuga Frean; Marco Colleoni; Gustavo Werutsky; Sabine Seiler; Nicole Burchardi; Valentina Nekljudova; and Gunter von Minckwitz |
| 264 | 1 | |c April 1, 2021 | |
| 300 | |a 24 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a 13 gezählte Seiten, 11 ungezählte Seiten (Supplement) | ||
| 500 | |a Gesehen am 29.09.2021 | ||
| 520 | |a PURPOSE - - About one third of patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer who have residual invasive disease after neoadjuvant chemotherapy (NACT) will relapse. Thus, additional therapy is needed. Palbociclib is a cyclin-dependent kinase 4 and 6 inhibitor demonstrating efficacy in the metastatic setting. - - PATIENTS AND METHODS - - PENELOPE-B (NCT01864746) is a double-blind, placebo‐controlled, phase III study in women with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer without a pathological complete response after taxane‐containing NACT and at high risk of relapse (clinical pathological staging-estrogen receptor grading score ≥ 3 or 2 and ypN+). Patients were randomly assigned (1:1) to receive 13 cycles of palbociclib 125 mg once daily or placebo on days 1-21 in a 28-day cycle in addition to endocrine therapy (ET). Primary end point is invasive disease-free survival (iDFS). Final analysis was planned after 290 iDFS events with a two-sided efficacy boundary P < .0463 because of two interim analyses. - - RESULTS - - One thousand two hundred fifty patients were randomly assigned. The median age was 49.0 years (range, 19-79), and the majority were ypN+ with Ki-67 ≤ 15%; 59.4% of patients had a clinical pathological staging-estrogen receptor grading score ≥ 3. 50.1% received aromatase inhibitor, and 33% of premenopausal women received a luteinizing hormone releasing hormone analog in addition to either tamoxifen or an aromatase inhibitor. After a median follow-up of 42.8 months (92% complete), 308 events were confirmed. Palbociclib did not improve iDFS versus placebo added to ET-stratified hazard ratio, 0.93 (95% repeated CI, 0.74 to 1.17) and two-sided weighted log-rank test (Cui, Hung, and Wang) P = .525. There was no difference among the subgroups. Most common related serious adverse events were infections and vascular disorders in 113 (9.1%) patients with no difference between the treatment arms. Eight fatal serious adverse events (two palbociclib and six placebo) were reported. - - CONCLUSION - - Palbociclib for 1 year in addition to ET did not improve iDFS in women with residual invasive disease after NACT. | ||
| 700 | 1 | |a Marmé, Frederik |d 1974- |e VerfasserIn |0 (DE-588)132561972 |0 (DE-627)52394893X |0 (DE-576)299226549 |4 aut | |
| 700 | 1 | |a Martin, Miguel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Untch, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bonnefoi, Hervé |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kim, Sung-Bae |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bear, Harry |e VerfasserIn |4 aut | |
| 700 | 1 | |a McCarthy, Nicole |e VerfasserIn |4 aut | |
| 700 | 1 | |a Melé Olivé, Mireia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gelmon, Karen |e VerfasserIn |4 aut | |
| 700 | 1 | |a García-Sáenz, José |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kelly, Catherine M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Reimer, Toralf |e VerfasserIn |4 aut | |
| 700 | 1 | |a Toi, Masakazu |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rugo, Hope S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Denkert, Carsten |d 1969- |e VerfasserIn |0 (DE-588)118129929 |0 (DE-627)079261124 |0 (DE-576)291730604 |4 aut | |
| 700 | 1 | |a Gnant, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Makris, Andreas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Koehler, Maria |e VerfasserIn |4 aut | |
| 700 | 1 | |a Huang-Bartelett, Cynthia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lechuga Frean, Maria Jose |e VerfasserIn |4 aut | |
| 700 | 1 | |a Colleoni, Marco |e VerfasserIn |4 aut | |
| 700 | 1 | |a Werutsky, Gustavo |e VerfasserIn |4 aut | |
| 700 | 1 | |a Seiler, Sabine |e VerfasserIn |4 aut | |
| 700 | 1 | |a Burchardi, Nicole |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nekljudova, Valentina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Minckwitz, Gunter von |d 1964- |e VerfasserIn |0 (DE-588)172260035 |0 (DE-627)673296962 |0 (DE-576)133128202 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology |d Alexandria, Va. : American Society of Clinical Oncology, 1983 |g 39(2021), 14, Seite 1518-1530 |h Online-Ressource |w (DE-627)313116962 |w (DE-600)2005181-5 |w (DE-576)090887018 |x 1527-7755 |7 nnas |a Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer the Penelope-B trial |
| 773 | 1 | 8 | |g volume:39 |g year:2021 |g number:14 |g pages:1518-1530 |g extent:24 |a Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer the Penelope-B trial |
| 856 | 4 | 0 | |u https://doi.org/10.1200/JCO.20.03639 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://ascopubs.org/doi/10.1200/JCO.20.03639 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210929 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 132561972 |a Marmé, Frederik |m 132561972:Marmé, Frederik |d 60000 |d 61300 |d 50000 |e 60000PM132561972 |e 61300PM132561972 |e 50000PM132561972 |k 0/60000/ |k 1/60000/61300/ |k 0/50000/ |p 2 | ||
| 999 | |a KXP-PPN1772026336 |e 398202689X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"title":[{"subtitle":"JCO : an American Society of Clinical Oncology journal","title_sort":"Journal of clinical oncology","title":"Journal of clinical oncology"}],"corporate":[{"role":"isb","display":"American Society of Clinical Oncology"}],"origin":[{"dateIssuedDisp":"1983-","publisher":"American Society of Clinical Oncology ; Lippincott Williams & Wilkins","publisherPlace":"Alexandria, Va. ; Baltimore, Md. [u.a.]","dateIssuedKey":"1983"}],"note":["Fortsetzung der Druck-Ausgabe","Gesehen am 22.05.23"],"physDesc":[{"extent":"Online-Ressource"}],"part":{"issue":"14","extent":"24","pages":"1518-1530","year":"2021","volume":"39","text":"39(2021), 14, Seite 1518-1530"},"id":{"issn":["1527-7755"],"zdb":["2005181-5"],"eki":["313116962"]},"language":["eng"],"titleAlt":[{"title":"official journal of the American Society of Clinical Oncology"},{"title":"JCO"},{"title":"Journal of clinical oncology legacy archive (ASCO)"}],"disp":"Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer the Penelope-B trialJournal of clinical oncology","recId":"313116962","type":{"bibl":"periodical","media":"Online-Ressource"},"pubHistory":["1.1983 -"]}],"note":["13 gezählte Seiten, 11 ungezählte Seiten (Supplement)","Gesehen am 29.09.2021"],"physDesc":[{"extent":"24 S."}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"doi":["10.1200/JCO.20.03639"],"eki":["1772026336"]},"language":["eng"],"title":[{"subtitle":"the Penelope-B trial","title_sort":"Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer","title":"Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer"}],"person":[{"family":"Loibl","given":"Sibylle","display":"Loibl, Sibylle","role":"aut"},{"role":"aut","display":"Marmé, Frederik","given":"Frederik","family":"Marmé"},{"role":"aut","family":"Martin","display":"Martin, Miguel","given":"Miguel"},{"family":"Untch","display":"Untch, Michael","given":"Michael","role":"aut"},{"role":"aut","display":"Bonnefoi, Hervé","given":"Hervé","family":"Bonnefoi"},{"given":"Sung-Bae","display":"Kim, Sung-Bae","family":"Kim","role":"aut"},{"role":"aut","family":"Bear","display":"Bear, Harry","given":"Harry"},{"role":"aut","given":"Nicole","display":"McCarthy, Nicole","family":"McCarthy"},{"role":"aut","family":"Melé Olivé","display":"Melé Olivé, Mireia","given":"Mireia"},{"given":"Karen","display":"Gelmon, Karen","family":"Gelmon","role":"aut"},{"family":"García-Sáenz","given":"José","display":"García-Sáenz, José","role":"aut"},{"role":"aut","family":"Kelly","display":"Kelly, Catherine M.","given":"Catherine M."},{"role":"aut","given":"Toralf","display":"Reimer, Toralf","family":"Reimer"},{"display":"Toi, Masakazu","given":"Masakazu","family":"Toi","role":"aut"},{"family":"Rugo","given":"Hope S.","display":"Rugo, Hope S.","role":"aut"},{"role":"aut","family":"Denkert","given":"Carsten","display":"Denkert, Carsten"},{"family":"Gnant","display":"Gnant, Michael","given":"Michael","role":"aut"},{"family":"Makris","given":"Andreas","display":"Makris, Andreas","role":"aut"},{"role":"aut","family":"Koehler","display":"Koehler, Maria","given":"Maria"},{"role":"aut","display":"Huang-Bartelett, Cynthia","given":"Cynthia","family":"Huang-Bartelett"},{"role":"aut","given":"Maria Jose","display":"Lechuga Frean, Maria Jose","family":"Lechuga Frean"},{"display":"Colleoni, Marco","given":"Marco","family":"Colleoni","role":"aut"},{"family":"Werutsky","given":"Gustavo","display":"Werutsky, Gustavo","role":"aut"},{"role":"aut","given":"Sabine","display":"Seiler, Sabine","family":"Seiler"},{"role":"aut","given":"Nicole","display":"Burchardi, Nicole","family":"Burchardi"},{"role":"aut","family":"Nekljudova","display":"Nekljudova, Valentina","given":"Valentina"},{"role":"aut","family":"Minckwitz","given":"Gunter von","display":"Minckwitz, Gunter von"}],"recId":"1772026336","name":{"displayForm":["Sibylle Loibl; Frederik Marmé; Miguel Martin; Michael Untch; Hervé Bonnefoi; Sung-Bae Kim; Harry Bear; Nicole McCarthy; Mireia Melé Olivé; Karen Gelmon; José García-Sáenz; Catherine M. Kelly; Toralf Reimer; Masakazu Toi; Hope S. Rugo; Carsten Denkert; Michael Gnant; Andreas Makris; Maria Koehler; Cynthia Huang-Bartelett; Maria Jose Lechuga Frean; Marco Colleoni; Gustavo Werutsky; Sabine Seiler; Nicole Burchardi; Valentina Nekljudova; and Gunter von Minckwitz"]},"origin":[{"dateIssuedDisp":"April 1, 2021","dateIssuedKey":"2021"}]} | ||
| SRT | |a LOIBLSIBYLPALBOCICLI1202 | ||